持续时间的抗血小板药物药物洗脱支架的研究
![In patients receiving drug-eluting stents, dual antiplatelet therapy can be safely discontinued during the first year, according to two studies published online Sept. 19 in the Journal of the American College of Cardiology. 持续时间的抗血小板药物药物洗脱支架的研究](https://scx1.b-cdn.net/csz/news/800a/2012/durationofan.jpg)
(每日健康)——接受药物洗脱支架的病人,双重抗血小板治疗可以安全地停止在第一年,据9月19日在网上发表的两项研究美国心脏病学会杂志》上。
在第一项研究中,Ignacio Ferreira-Gonzalez,医学博士,Ph.D., from Vall d'Hebron Hospital in Barcelona, Spain, and colleagues conducted a study involving 1,622 patients undergoing drug-eluting stent implantation. The patients were assessed at regular intervals up to a year post-implantation. During that time, 10.6 percent interrupted at least one antiplatelet drug; 64.5 percent of the interruptions were temporary. The researchers found that the rate of major cardiac events was similar in patients who continued or interrupted treatment.
在第二项研究中,Byeong-Keuk金,医学博士,from the Yonsei University College of Medicine in Seoul, South Korea, and colleagues randomly assigned 2,117 patients with coronary artery stenosis to receive a zotarolimus-eluting stent with three months of dual抗血小板治疗或其他药物洗脱支架与12个月的双重抗血小板治疗。研究人员发现,两组有相似的主要复合终点的几率心血管死亡,心肌梗死支架血栓形成,目标或血管血管再生,或出血一年在每组(4.7%)。
”新一代药物洗脱支架,六个月的双重抗血小板治疗可能就足够了,三个月不完全异乎寻常的低风险组,“Bernhard Witzenbichler,医学博士,从Charite-Campus本杰明·富兰克林在柏林,在社论中写道。“然而,病人——和device-related标准安全允许双重抗血小板治疗早期撤军或中断还有待确定。”
Ferreira-Gonzalez研究部分由百时美施贵宝;两位作者披露金融与毒品和设备公司。两位作者金研究披露金融关系美敦力公司。
更多信息:抽象——Ferreira-Gonzalez
全文
抽象——金
全文
编辑
版权©2012每日健康。保留所有权利。